Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit gene and response to lithium prophylaxis in mood disorders

Alessandro Serretti, Roberta Lilli, Cristina Lorenzi, Linda Franchini, Daniela Di Bella, Marco Catalano, Enrico Smeraldi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Lithium is an effective prophylactic agent in mood disorders, and genetic factors are likely to modulate individual susceptibility to lithium treatment. The aim of this study is to investigate the influence of dopamine receptor D2 (DRD2), D4 exon 3 (DRD4), and γ-aminobutyric acid type A (GABA(A)) receptor alpha-1 subunit (GABRA1) gene variants on the efficacy of lithium prophylaxis in mood disorders. Patients with mood disorders (N=125: bipolar subtype, n=100; major depressive disorder subtype, n=25) were followed prospectively for an average of 53 months and were typed for DRD2 (Ser311/Cys311: n=121, VNTR: n=63), DRD4 (n=125) and GABRA1 (n=61) variants using polymerase chain reaction (PCR) techniques. DRD2, DRD4 and GABRA1 variants were not associated with response to lithium. A trend was observed toward a better outcome of DRD4*2/4 subjects, but it was due to only two subjects. Consideration of possible stratification effects like gender, polarity, family history, age at onset and duration of lithium treatment did not reveal any association either. DRD2, DRD4 and GABRA1 variants therefore do not appear to be associated with the outcome of lithium prophylaxis in mood disorders. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)7-19
Number of pages13
JournalPsychiatry Research
Volume87
Issue number1
DOIs
Publication statusPublished - Jul 30 1999

Fingerprint

Dopamine D4 Receptors
Mood Disorders
Lithium
gamma-Aminobutyric Acid
Exons
Dopamine D2 Receptors
Genes
Major Depressive Disorder
GABA-A Receptors
Age of Onset
Polymerase Chain Reaction
Therapeutics

Keywords

  • Bipolar disorder
  • Dopamine receptor D2
  • Dopamine receptor D4
  • Follow-up studies
  • GABA(A) receptors
  • Genetics
  • Treatment outcome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit gene and response to lithium prophylaxis in mood disorders. / Serretti, Alessandro; Lilli, Roberta; Lorenzi, Cristina; Franchini, Linda; Di Bella, Daniela; Catalano, Marco; Smeraldi, Enrico.

In: Psychiatry Research, Vol. 87, No. 1, 30.07.1999, p. 7-19.

Research output: Contribution to journalArticle

Serretti, Alessandro ; Lilli, Roberta ; Lorenzi, Cristina ; Franchini, Linda ; Di Bella, Daniela ; Catalano, Marco ; Smeraldi, Enrico. / Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit gene and response to lithium prophylaxis in mood disorders. In: Psychiatry Research. 1999 ; Vol. 87, No. 1. pp. 7-19.
@article{264f294b60a24bb98435eceada8e961b,
title = "Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit gene and response to lithium prophylaxis in mood disorders",
abstract = "Lithium is an effective prophylactic agent in mood disorders, and genetic factors are likely to modulate individual susceptibility to lithium treatment. The aim of this study is to investigate the influence of dopamine receptor D2 (DRD2), D4 exon 3 (DRD4), and γ-aminobutyric acid type A (GABA(A)) receptor alpha-1 subunit (GABRA1) gene variants on the efficacy of lithium prophylaxis in mood disorders. Patients with mood disorders (N=125: bipolar subtype, n=100; major depressive disorder subtype, n=25) were followed prospectively for an average of 53 months and were typed for DRD2 (Ser311/Cys311: n=121, VNTR: n=63), DRD4 (n=125) and GABRA1 (n=61) variants using polymerase chain reaction (PCR) techniques. DRD2, DRD4 and GABRA1 variants were not associated with response to lithium. A trend was observed toward a better outcome of DRD4*2/4 subjects, but it was due to only two subjects. Consideration of possible stratification effects like gender, polarity, family history, age at onset and duration of lithium treatment did not reveal any association either. DRD2, DRD4 and GABRA1 variants therefore do not appear to be associated with the outcome of lithium prophylaxis in mood disorders. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "Bipolar disorder, Dopamine receptor D2, Dopamine receptor D4, Follow-up studies, GABA(A) receptors, Genetics, Treatment outcome",
author = "Alessandro Serretti and Roberta Lilli and Cristina Lorenzi and Linda Franchini and {Di Bella}, Daniela and Marco Catalano and Enrico Smeraldi",
year = "1999",
month = "7",
day = "30",
doi = "10.1016/S0165-1781(99)00056-6",
language = "English",
volume = "87",
pages = "7--19",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit gene and response to lithium prophylaxis in mood disorders

AU - Serretti, Alessandro

AU - Lilli, Roberta

AU - Lorenzi, Cristina

AU - Franchini, Linda

AU - Di Bella, Daniela

AU - Catalano, Marco

AU - Smeraldi, Enrico

PY - 1999/7/30

Y1 - 1999/7/30

N2 - Lithium is an effective prophylactic agent in mood disorders, and genetic factors are likely to modulate individual susceptibility to lithium treatment. The aim of this study is to investigate the influence of dopamine receptor D2 (DRD2), D4 exon 3 (DRD4), and γ-aminobutyric acid type A (GABA(A)) receptor alpha-1 subunit (GABRA1) gene variants on the efficacy of lithium prophylaxis in mood disorders. Patients with mood disorders (N=125: bipolar subtype, n=100; major depressive disorder subtype, n=25) were followed prospectively for an average of 53 months and were typed for DRD2 (Ser311/Cys311: n=121, VNTR: n=63), DRD4 (n=125) and GABRA1 (n=61) variants using polymerase chain reaction (PCR) techniques. DRD2, DRD4 and GABRA1 variants were not associated with response to lithium. A trend was observed toward a better outcome of DRD4*2/4 subjects, but it was due to only two subjects. Consideration of possible stratification effects like gender, polarity, family history, age at onset and duration of lithium treatment did not reveal any association either. DRD2, DRD4 and GABRA1 variants therefore do not appear to be associated with the outcome of lithium prophylaxis in mood disorders. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Lithium is an effective prophylactic agent in mood disorders, and genetic factors are likely to modulate individual susceptibility to lithium treatment. The aim of this study is to investigate the influence of dopamine receptor D2 (DRD2), D4 exon 3 (DRD4), and γ-aminobutyric acid type A (GABA(A)) receptor alpha-1 subunit (GABRA1) gene variants on the efficacy of lithium prophylaxis in mood disorders. Patients with mood disorders (N=125: bipolar subtype, n=100; major depressive disorder subtype, n=25) were followed prospectively for an average of 53 months and were typed for DRD2 (Ser311/Cys311: n=121, VNTR: n=63), DRD4 (n=125) and GABRA1 (n=61) variants using polymerase chain reaction (PCR) techniques. DRD2, DRD4 and GABRA1 variants were not associated with response to lithium. A trend was observed toward a better outcome of DRD4*2/4 subjects, but it was due to only two subjects. Consideration of possible stratification effects like gender, polarity, family history, age at onset and duration of lithium treatment did not reveal any association either. DRD2, DRD4 and GABRA1 variants therefore do not appear to be associated with the outcome of lithium prophylaxis in mood disorders. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Bipolar disorder

KW - Dopamine receptor D2

KW - Dopamine receptor D4

KW - Follow-up studies

KW - GABA(A) receptors

KW - Genetics

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0032828965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032828965&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(99)00056-6

DO - 10.1016/S0165-1781(99)00056-6

M3 - Article

C2 - 10512150

AN - SCOPUS:0032828965

VL - 87

SP - 7

EP - 19

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -